Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 138

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 138
---
 30 2024 we paid £93,000 in respect of lease liabilities compared
with £95,000 in the prior period.

In 2023 we paid £0.19 million in respect
of lease liabilities compared with £0.18 million in 2022, this related to rental payments on our facilities in Cardiff.

Shares Issues Including Warrants, Net of Costs. We raised £4.74 million in net proceeds in the six months ended June 30, 2024
from a warrant inducement transaction in May 2024 private placement. We raised £6.35 million in net proceeds in the six months ended
June 30, 2023 from a private placement in February 2023 and a registered direct offering in May 2023, as well as from warrants exercises.

We
raised £10.43 million in net proceeds during the year ended December 31, 2023 in cash from private placements of our securities,
a registered direct offering and an underwritten public offering, as well as from the exercise of warrants. We raised £0.24 million
in net proceeds during the year ended December 31, 2022 in cash from the registered direct offering in December 2022 and from the exercise
of warrants.

Cash and Cash Equivalents

Cash decreased for the six
months ended June 30, 2024 by £0.92 million, compared to an increase of £2.39 million in the corresponding period in 2023.
As at June 30, 2024, we had cash and cash equivalents of £5.06 million as compared to £5.23 million as at June 30, 2023.

Cash
increased for the year ended December 31, 2023 by £3.14 million, before the impact of foreign exchange movements, compared to an
decrease of £7.22 million in 2022. This increase was primarily due to funds received from financing activities offset by continuing
trading losses. As of December 31, 2023, we had cash and cash equivalents of £5.97 million compared to £2.84 million as at
December 31, 2022.

| 70 |

Cash Commitments

As of June 30, 2024, our cash
resources were expected to provide liquidity into the first quarter of 2025. The Company remains focused on tight control of its cash
commitments at any given time. As of June 30